Melanoma

During a live event, Daniel Olson, MD, discussed data and experience using tumor-infiltrating lymphocytes in melanoma.

The NCCN guidelines now include the Merlin CP-GEP assay as part of shared decision-making for a sentinel lymph node biopsy in patients with melanoma.

Circulating tumor DNA showed potential as a dynamic biomarker in assessing response to immune checkpoint inhibitors in melanoma.

A retrospective study of tumor-infiltrating lymphocyte therapy showed that despite its benefit, many patients were unable to receive lifileucel.

Real-world data show over an 40% response rate for lifileucel TIL therapy, indicating that those treated earlier did better and fewer doses of IL-2 could be used effectively.

The FDA granted orphan drug designation to IFx-2.0, an injection designed to enhance immune response, in cutaneous melanoma.

Neoadjuvant pembrolizumab showed promising high response rates and melanoma-specific survival outcomes in desmoplastic melanoma.

The FDA gave clearance to the IND for a randomized trial of the DNA vaccine iSCIB1+ based on positive single-arm data in combination with dual checkpoint inhibitors.

An mRNA neoantigen therapy maintained long-term recurrence-free survival as an adjuvant for melanoma, compared with pembrolizumab alone.

During a live event, Omid Hamid, MD, discussed the logistics and multidisciplinary process of using tumor-infiltrating lymphocytes in patients with melanoma.

A retrospective study of patients treated with an alternate dose schedule of ipilimumab plus nivolumab in advanced melanoma found improvements in both tolerability and efficacy.

A recent analysis highlights the efficacy of melphalan/HDS for metastatic uveal melanoma, showing improved outcomes in patients with lower hepatic tumor burden.

Melanoma treatment advances with lifileucel's promising efficacy, regulatory updates, and innovative therapies, shaping a hopeful landscape for patients.

New trial results reveal nivolumab plus relatlimab fails to improve recurrence-free survival in resected stage III-IV melanoma, prompting further research.

Recent study results highlight the critical impact of comorbidities on survival rates among patients with melanoma, emphasizing the need for integrated cancer care strategies.

Lifileucel shows sustained efficacy and safety in advanced melanoma, highlighting its potential as a key treatment for ICI-resistant cases.

FDA designates NBM-BMX as an orphan drug for metastatic uveal melanoma, highlighting its potential in treating this aggressive cancer.

The IGNYTE trial reveals that RP1 combined with nivolumab offers significant, durable responses in advanced melanoma patients previously resistant to anti-PD-1 therapy.

Physicians at VCU's Massey Comprehensive Cancer Center explored their experiences using tumor-infiltrating lymphocytes to treat patients with advanced melanoma.

Groundbreaking studies reveal the potential of cell therapies to achieve long-term remission in HPV-associated cancers, transforming treatment options for patients.

New clinical trial data highlight the promising antitumor effects of imneskibart combined with aldesleukin in patients with melanoma or NSCLC.

Vishal A. Patel, MD, discusses the FDA approval of cemiplimab in cutaneous squamous cell carcinoma.

A phase 2 trial yielded encouraging results for pembrolizumab plus lenvatinib in uveal melanoma, showing promising progression-free survival rates.

New findings from the CheckMate 238 trial highlight nivolumab's superior long-term efficacy over ipilimumab in treating advanced melanoma.

BNT111 combined with cemiplimab shows promising efficacy in treating PD-(L)1-relapsed melanoma, achieving significant response rates and manageable safety profiles.